Ben Wolfson

I’m a postdoctoral fellow in cancer immunotherapy where I’m focused on rapidly bringing combination therapies to the clinic and identifying novel off-label use cases for standard-of-care therapies and identifying new treatment strategies for underserved patient populations.

I’m also passionate about the intersection between science/technology and society, policy and the future, and enjoy exploring these fields through my own personal research and writing. I’m a contributor to Reboot HQ where I review books on tech, science and society and interview authors about once a month, and  am an Associate Editor at the Journal of Science Policy and Governance, where I enjoy helping other early-career writers craft well written news and policy articles.

 

______________________________________________________________________________

 

Recent Posts

  • Science Policy Around the Web November 17, 2020
    On Monday, biotech firm Moderna announced preliminary findings of their COVID-19 vaccine clinical trial demonstrating 94.5% efficacy. Moderna reported that 90 people who had received placebo shots became ill with COVID-19, compared to only 5 in the vaccine group. Moreover, of the 90 positive patients in the placebo group 11 developed severe cases of COVID-19, compared to no severe cases in the treatment group. These findings come a week after Pfizer and Biontech announced that preliminary findings from their own vaccine clinical trial had demonstrated that the vaccine was more than 90% effective….
  • How Goliath ate David: the story of Instagram
    Sarah Frier’s deft narrative nonfiction begins as a riveting tale of startup drama, with Instagram’s historic sale to Facebook for $1 billion and a guarantee of business independence. But what follows in No Filter is the story of culture clash and an ongoing debate between curation and automation, ending with (spoiler alert!) the exit of Instagram co-founders Kevin Systrom and Mike Krieger…
  • Science Policy Around the Web June 16th, 2020
    In the past two weeks, technology companies IBM and Microsoft have announced that they would no longer sell facial recognition technology, and Amazon implemented a one-year moratorium of their own facial recognition software. These policy changes come in the wake of widespread protests across America in response to police violence…
  • Science Policy Around the Web April 21st, 2020
    Originally published at sciencepolicyforall.wordpress.com EPA can’t bar grantees from sitting on science advisory panels, judge rules In February of this year, Judge Denise Cote for the U.S. District Court for the Southern District of New York ruled against the Environmental Protection Agency (EPA) in a suit brought by the Natural Resource Defense Council (NRDC) contesting […]
  • Science Policy Around the Web March 12th, 2020
    Originally published sciencepolicyforall.wordpress.com Fired cancer scientist says ‘good people are being crushed’ by overzealous probes into possible Chinese ties Recent months have seen major developments in the FBI and NIH’s investigation into ties between U.S. research labs and China, with the highest profile case to date alleging that the head of the Harvard Chemistry Department […]